See more : KL Acquisition Corp (KLAQU) Income Statement Analysis – Financial Results
Complete financial analysis of Freeline Therapeutics Holdings plc (FRLN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Freeline Therapeutics Holdings plc, a leading company in the Biotechnology industry within the Healthcare sector.
- Tibet Tourism Co.,Ltd (600749.SS) Income Statement Analysis – Financial Results
- Meggitt PLC (MGGT.L) Income Statement Analysis – Financial Results
- Vista Alegre Atlantis, SGPS, S.A. (VAF.LS) Income Statement Analysis – Financial Results
- Wellfully Limited (WFL.AX) Income Statement Analysis – Financial Results
- Coca-Cola FEMSA, S.A.B. de C.V. (COCSF) Income Statement Analysis – Financial Results
Freeline Therapeutics Holdings plc (FRLN)
About Freeline Therapeutics Holdings plc
Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies for patients suffering from inherited systemic debilitating diseases. Its advanced product candidate is verbrinacogene setparvovec (FLT180a), a gene therapy product candidate that is in Phase 1/2 clinical trials in adult males for the treatment of hemophilia B. The company's products also include FLT190, which is in Phase 1/2 clinical trial for the treatment of Fabry disease; and FLT201, a liver-directed gene therapy product candidate to treat type 1 Gaucher disease and is under Phase 1/2 clinical trial. In addition, it has research programs in various indications for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 1.74M | 2.39M | 1.93M | 1.55M | 0.00 |
| Gross Profit | -1.74M | -2.39M | -1.93M | -1.55M | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 66.20M | 95.43M | 76.15M | 47.04M | 34.19M |
| General & Administrative | 30.66M | 44.57M | 26.30M | 16.60M | 6.79M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 30.66M | 44.57M | 26.30M | 16.60M | 6.79M |
| Other Expenses | -1.57M | -2.09M | -15.27M | -10.60M | -390.00K |
| Operating Expenses | 95.29M | 137.91M | 87.18M | 53.05M | 32.72M |
| Cost & Expenses | 95.29M | 137.91M | 87.18M | 53.05M | 32.72M |
| Interest Income | 904.00K | 403.95K | 275.00K | 74.31K | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 151.00K |
| Depreciation & Amortization | 1.27M | 9.24M | 17.18M | 12.14M | 970.00K |
| EBITDA | -97.17M | -133.14M | -85.27M | -51.51M | -32.14M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -98.45M | -142.38M | -102.45M | -63.64M | -40.98M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 9.84M | 2.33M | 6.26M | 9.88M | -470.80K |
| Income Before Tax | -88.60M | -140.05M | -96.19M | -53.77M | -33.26M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 368.00K | 342.00K | 129.00K | 141.00K | 27.00K |
| Net Income | -88.97M | -140.39M | -96.32M | -53.91M | -33.28M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -22.52 | -58.98 | -102.09 | -127.39 | -78.65 |
| EPS Diluted | -22.52 | -58.98 | -102.09 | -127.39 | -78.65 |
| Weighted Avg Shares Out | 3.95M | 2.38M | 943.52K | 423.19K | 423.19K |
| Weighted Avg Shares Out (Dil) | 3.95M | 2.38M | 943.52K | 423.19K | 423.19K |
Freeline Announces Executive Leadership Changes
Freeline Doses Second Patient of Phase 1/2 MARVEL-1 Clinical Trial for Fabry Disease
Freeline to Present Data at the American Society of Gene and Cell Therapy Annual Meeting 2021
Freeline to Participate in Upcoming Investor Conferences in April and May 2021
Freeline Reports Full Year 2020 Financial Results and Business Highlights
Freeline to Present at Upcoming Investor Conferences
Freeline Presents Data on its Gaucher Disease and Fabry Disease AAV-Based Gene Therapies at the 17th Annual WORLDSymposium™
U.S. IPO Week Ahead: Canadian IT And German Chemicals Lead A Diverse 9-IPO Week
Freeline to Present Data at the 2021 Virtual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) and the 17th Annual WORLDSymposium™ 2021
Freeline to participate at Conferences during January 2021
Source: https://incomestatements.info
Category: Stock Reports